Navigation area


BioRN

BioRN

The objective of the BioRN cluster is to occupy and maintain a leading position in Europe in the field of personalised medicine and cancer.

Personalised medicine to fight cancer

Innovative products and methods in red biotechnology

Many people with complex diseases like cancer do not undergo comprehensive treatment with one conventional form of therapy as they react differently to the drugs used. Thanks to personalised medicine, diseases will be diagnosed more accurately in the future and treated in accordance with the result.

The projects of the Leading-Edge Cluster "Cell-Based & Molecular Medicine in the Metropolitan Region Rhine-Neckar" concentrate on the areas personalised medicine and cancer. Innovative biotech know-how is translated into industrially mature products at the location and thus brought even closer to the market. The products include drug candidates, diagnostic testing systems and technology platforms.

The Biotechnology Cluster Rhine-Neckar (BioRN) in and around Heidelberg embraces some 100 partners from industry, science and politics. These include the German Cancer Research Center (DKFZ), the University of Heidelberg, the Heidelberg University Hospital and the European Molecular Biology Laboratory (EMBL), as well as the health care companies Roche (Mannheim), Abbott (Ludwigshafen) and Merck-Serono (Darmstadt).

The objective of the BioRN cluster is to occupy and maintain a leading position in Europe in the field of personalised medicine and cancer.

 

Additional information

Deutsche Version dieser Seite
(URL: http://www.bmbf.de/de/15150.php)

Contact Persons

  • BioRN

    • Geschäftsführer BioRN Cluster Management GmbH
    • Dr. Christian Tidona
    • Im Neuenheimer Feld 582
    • 69120 Heidelberg
    • Telefonnummer: 06221/65578-0
    • E-Mail-Adresse: info@biorn.org
    • Homepage: http://www.biorn.org
 

© 04/19/2014 04:23 Bundesministerium für Bildung und Forschung